;

House Publications

The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication

Order Paper and Notice Paper

Bilingual view PDF

Notice Paper

No. 353

Thursday, October 10, 2024

10:00 a.m.

Introduction of Government Bills

Introduction of Private Members' Bills

October 9, 2024 — — Bill entitled “An Act to amend the Canada Labour Code (flight attendants)”.

Notices of Motions (Routine Proceedings)

October 9, 2024 — — That the second report of the Special Joint Committee on the Declaration of Emergency, presented on Monday, October 7, 2024, be concurred in.

October 9, 2024 — — That the 20th report of the Standing Committee on Foreign Affairs and International Development, presented on Friday, June 16, 2023, be concurred in.

Questions

Q-3064² — October 9, 2024 — — With regard to expenditures related to the cabinet retreat which took place in Halifax, Nova Scotia, from August 25 to 27, 2024, including expenses incurred by the Privy Council Office as well as by other departments or agencies, and including travel expenses incurred by ministers, ministerial staff, and others: (a) what are the total expenditures related to the retreat incurred to date; (b) what is the breakdown of the expenditures by type of expense (accommodation, hospitality, audio-visual, etc.); (c) what are the details of all expenditures in excess of $1,000, including, for each, the (i) amount, (ii) vendor, (iii) description of the goods or services provided; and (d) what are the details of all travel expenses incurred by ministers and their staff, broken down by individual, including, for each, the (i) title, (ii) amount spent on airfare, (iii) amount spent on other transportation, (iv) amount spent on accommodation, (v) hotel or venue name, (vi) amount spent on meals or per diems, (vii) other expenses, broken down by type?

Q-3065² — October 9, 2024 — — With regard to government expenditures on "other furniture and fixtures including parts" (Treasury Board code 1246 or similar), since April 1, 2022, and broken down by fiscal year: (a) what was the total amount spent on such services, broken down by department, agency, or other government entity; and (b) what are the details of each expenditure, including the (i) date, (ii) vendor, (iii) amount, (iv) description of the services, (v) details of how the contract was awarded (sole-sourced or competitive bid)?

Q-3066² — October 9, 2024 — — With regard to the CRA and small businesses which qualify for the small business deduction: what was the total amount paid by small businesses in federal corporate taxes, broken down by each of the last five fiscal years?

Q-3067² — October 9, 2024 — — With regard to government expenditures on "office furniture and furnishings, including parts" (Treasury Board code 1231 or similar), since April 1, 2022, and broken down by fiscal year: (a) what was the total amount spent on such services, broken down by department, agency, or other government entity; and (b) what are the details of each expenditure, including the (i) date, (ii) vendor, (iii) amount, (iv) description of the services, (v) details of how the contract was awarded (sole-sourced or competitive bid)?

Q-3068² — October 9, 2024 — — With regard to Health Canada’s (HC) and the Public Health Agency of Canada’s (PHAC) decision to withdraw the market authorization and destruction of the COVID-19 XBB.1.5 vaccines and future assessment of upcoming mRNA vaccines: (a) are there material differences between the XBB.1.5 COVID-19 vaccines and the new 2024-2025 formulation beyond the mRNA coding for a different spike protein strain; (b) if (a) is affirmative, what are the differences; (c) if the answer to (a) is affirmative, how will Canadians processing claims against the vaccine manufacturers be able to prove their allegations when physical evidence is required and has been destroyed; (d) what is the estimated number of COVID-19 vaccine vials that will be destroyed, broken down by manufacturer (Pfizer, Moderna, AstraZeneca, others); (e) what is the estimated dollar cost to Canadians to destroy these vaccine products, per vaccine and in total; (f) what is the regulatory process for COVID-19 vaccines which resulted in a “contractual obligation for Health Canada to withdraw all XBB products from the market until a lot could be released and distributed in Canada” (Global news); (g) what is the contractual obligation in (f) and with whom; (h) will provinces be able to order any interim supply of the COVID-19 XBB vaccines and, if not, why not; (i) with respect to the statement made by Pfizer/BioNTech on October 20, 2023, found on page 56 of Access to Information and Privacy (ATIP) 2024-000097-2024-08-22, that Pfizer “would be open to discuss the outcome from the plasmid backbone modification evaluation with Health Canada”, does HC expect the removal of the SV40 sequences from the updated Pfizer/BioNTech COVID-19 vaccines for 2024-25; (j) is HC considering the assessment of future mRNA-based vaccines to continue under the Centre for Vaccines, Clinical Trials and Biostatistics or to be transferred to another Centre or Department within Biologic and Radiopharmaceutical Drugs Directorate or elsewhere; and, if so, what would be the criteria or rationale?

Q-3069² — October 9, 2024 — — With regard to communication and meetings between Attorney General David Lametti and Chief Justice Wagner from January 2020 to June 2022, and the Office of the Prime Minister (PMO) and Chief Justice Wagner during the same period: (a) how many times did the Attorney General and Chief Justice communicate with each other; (b) how many times did the PMO and Chief Justice communicate with each other; (c) what are the details of each communication in (a) and (b), including, the (i) date, (ii) subject, (iii) names of the people included in the communication, (iv) type of communication (e.g. email, phone, text, memorandum, messaging software, video conference, in person meeting, fax); (d) how many meetings occurred between (i) the Attorney General and the Chief Justice, (ii) the PMO and the Chief Justice; and (e) what are the details for each meeting in (d), including the (i) date, (ii) time, (iii) location, (iv) purpose of the meeting, (v) topics discussed in the meeting, (vi) meeting attendees, (vii) outcome of the meeting?

Q-3070² — October 9, 2024 — — With regard to Health Canada’s (HC) decision to approve the COVID-19 modRNA vaccines and the Prime Minister’s subsequent support for the vaccine mandates in the federal public sector and vaccine passports for travel purposes during the Covid-19 pandemic: (a) what is the immunological mechanism of action of the COVID-19 mRNA vaccines that enables them to stop the spread of SARS-CoV2; (b) what data supports the mechanism of action referred to in (a); (c) who or what agency provided the data and verified the data; (d) when was this data provided to (i) HC, (ii) the Prime Minister’s office; (e) what data did Pfizer and Moderna produce to HC that demonstrated (i) the period of time spike protein is produced in the body, (ii) where in the body the spike protein is produced; and (f) in relation to (e), what was the period of time Pfizer and Moderna tracked spike protein in their clinical studies?

Q-3071² — October 9, 2024 — — Regarding Health Canada’s (HC) review of the COVID-19 modRNA vaccine products: (a) did HC consider the specific nature of the nanotechnology of the lipid particles used for the modRNA vaccine delivery; (b) if affirmative to (a), what was their assessment; (c) why was the fact that modRNA vaccines contain nanotechnology omitted from the product monograph-label; (d) did HC assess the toxicity of pegylated nanoparticles, specifically the risk for complement activated related pseudoallergy (CARPA) with the lipid nanoparticles used in the mRNA vaccines; (e) if affirmative to (d), why was this not included in the product labelling; (f) if negative to (d) why wasn’t this assessed; (g) did HC assess the risk of toxicity due to the nanoformat of these vaccines; (h) if affirmative to (g), what was the assessment result; (i) if negative to (g), why not; (j) did HC assess the lipid nanoparticles as a novel excipient; (k) if affirmative to (j), what was the assessment; (l) if negative to (j), why not; (m) with respect to nanotechnology products and their unique properties and behaviors particularly in their application to the modRNA vaccines, did HC examine the (i) safety, (ii) effectiveness, (iii) risk to the environment and (iv) its specific regulatory status; (n) if affirmative to (m), (i) through to (iv), what were the assessment results; (o) if negative to (m), (i) through to (iv), why not; (p) how do established safe levels of DNA apply, (i) when using pegylated LNPs as a delivery system, (ii) when a product that contains pegylated LNPs requires repeated dosing; and (q) what assessment was performed to assess the risk of residual DNA when using pegylated LNPs as a delivery system in a vaccine which requires repeated dosing?

Q-3072² — October 9, 2024 — — With regard to Health Canada's (HC) establishing the safety of the Pfizer/BioNTech COVID-19 vaccine in 12-15 year olds: (a) what serious adverse events (SAEs) did the pharmaceutical company disclose to Canada's health agencies for this age group pre-authorization; (b) since approving the product in this age group, has the Public Health Agency of Canada (PHAC), the National Advisory Committee on lmmunization (NACI) or HC become aware of additional adverse events (AEs) or SAEs that the pharmaceutical company had not disclosed during the initial authorization process; (c) if the answer to (b) is affirmative, (i) what AEs and SAEs has the PHAC, the NACI and HC become aware of, (ii) when were they discovered, (iii) what are the means by which Canada's health agencies were provided this information; (d) prior to authorizing this product in this age group, was the PHAC, HC or the NACI given information about (i) the SAEs of a 12-year-old trial participant named Maddie de Geray who was diagnosed with chronic inflammatory demyelinating polyneuropathy which rendered her reliant on a wheelchair and feeding tube, (ii) any other specific SAE cases in this cohort following the Pfizer inoculation; (e) if the answer to (d) is affirmative, what was the date and means by which the PHAC, the NACI or HC became aware of these cases; (f) if the answer to (d) is negative, has Ms. De Geray's diagnoses been added to HC's list of SAEs on the HC website in this age group; (g) has the PHAC, HC or the NACI been aware that the adverse events experienced by trial participant Maddie de Geray were not properly disclosed within their trial studies as described in the scientific publication of said trial (i.e. NEJM - Frenck et al. 2021); (h) did the PHAC, HC or the NACI take any action after discovering the lack of proper disclosure of Maddie de Geray's SAEs by Pfizer; (i) what was the age stratified risk-benefit analysis for 12-15 year olds in relation to the Pfizer/BioNTech COVID-19 vaccine at the time of authorization, on May 5, 2021; (j) what was the data and calculations for quantifying the risks and benefits that Canadian health agencies used to authorize or approve the product in this age group; (k) what data indicated that the benefits of the vaccine outweighed the risks at the time of authorization; (l) since the roll-out of the Pfizer/BioNTech COVID-19 vaccine in this age group, (i) what are the top ten SAEs identified in this cohort, (ii) how have these SAEs been communicated to the medical community and the public at large; (m) what type and frequency of SAEs in 12-15-year-old would invoke an unfavourable benefits-risk ratio for healthy children and for children with underlying medical conditions; and (n) is HC, the PHAC or the NACI aware of any other jurisdictions worldwide that no longer recommends the mRNA COVID-19 vaccines in children at (i) six months of age, (ii) between six months and two years (iii) between two to five years, (iv) between five to 12 years, (v) between 12-15 year, (vi) between 15-18 years?

Notices of Motions for the Production of Papers

Business of Supply

Government Business

Private Members' Notices of Motions

M-133 — October 9, 2024 — — That, in the opinion of the House, the government should ensure that the Future of Sport in Canada Commission continues its work regardless of any possible call for an early election.

M-134 — October 9, 2024 — — That, in the opinion of the House, after completing the Future of Sport in Canada Commission and understanding the breadth and depth of the damage and hurt caused by a sport system that has failed athletes and other participants, the Prime Minister should formally apologize for that damage and hurt.

M-135 — October 9, 2024 — — That, in the opinion of the House:

(a) the focus of sport needs to be on improving the physical and mental health of Canadians, including young people and carded athletes; and

(b) the government should ensure our national sport system comes under the direction of Health Canada.

M-136 — October 9, 2024 — — That, in the opinion of the House, the government should permanently institute a Minister of Sport position responsible for:

(a) improving the health and fitness of Canadians, ensuring safe environments, and protections for athletes

(b) delivering a report on the health, safety, and wellbeing of carded athletes to be tabled in Parliament on a fixed schedule; and

(c) ensuring adequate resources for multisport service organizations, national sport organizations, carded athletes, community sport, and ending abuse in sport.

M-137 — October 9, 2024 — — That, in the opinion of the House, the Minister of Sport should work across international borders to develop a safe sport movement within the United Nations system and the Olympic and Paralympic systems.

M-138 — October 9, 2024 — — That, in the opinion of the House, the Minister of Sport should begin a long overdue discussion on: (a) the protection of the physical and mental health of athletes; (b) injury prevention; (c) overtraining; and (d) nutrition and disordered eating.

M-139 — October 9, 2024 — — That, in the opinion of the House, the Minister of Sport should:

(a) go beyond after-the-fact concussion protocols;

(b) ensure safe and reasonable action to protect athletes from permanent injury caused by repetitive concussive and subconcussive blows; and

M-140 — October 9, 2024 — — That, in the opinion of the House, the government should develop a registry to track concussions of carded athletes, and work with provinces and territories to share best practices.

M-141 — October 9, 2024 — — That, in the opinion of the House, the government should work with carded athletes to:

(a) specify athletes’ rights;

(b) specify and codify duty of care and level of protections to these athletes; and

M-142 — October 9, 2024 — — That, in the opinion of the House, the government should examine board membership rules for national sport organizations and mandate new rules based on its findings.

M-143 — October 9, 2024 — — That, in the opinion of the House, the government should tie national sport organization funding to progress being made on demonstrated and effective action on ending all forms of abuse in sport.

M-144 — October 9, 2024 — — That, in the opinion of the House, the government should mandate national sport organizations to increase financial transparency and publicly disclose, including but not limited to, all grants, capital funds, donations, fundraising, membership fees, partnerships, sponsorships, and insurance.

M-145 — October 9, 2024 — — That, in the opinion of the House, the government should recognize that:

(a) the sport system was founded on power imbalances, obedience, and deference to authority;

(b) abuse in sport is a longstanding, entrenched, public health crisis;

(d) codes of silence continue to exist around abuse.

M-146 — October 9, 2024 — — That, in the opinion of the House, the government should commit to end:

(a) emotional, physical, psychological, sexual, and verbal abuse and neglect in the sport system; and

(b) the continuing and flawed belief that abuse is a means to better performances.

M-147 — October 9, 2024 — — That, in the opinion of the House, the government should recognize that:

(a) safe sport should always be the primary goal of every sport, ahead of winning games, tournaments, and medals;

(b) everyone in the sport system has a role to play in protecting athletes and young people;

(d) division remains between those who want to remove abusers, and those who believe that the person irrespective of offence is the right person to get results.

M-148 — October 9, 2024 — — That, in the opinion of the House, the government should implement a zero-tolerance approach in the sport system on misogyny, discrimination, harassment, hazing, and racism, with consistent application of penalties.

M-149 — October 9, 2024 — — That, in the opinion of the House, the government should:

(a) implement a zero-tolerance approach on sexual assault involving an authority figure, athlete-perpetrated sexual assault, and athlete-perpetrated group sexual assault;

(b) ensure that reporting of such assaults is immediate and mandatory to law enforcement and the governing safe sport body; and

(c) ensure a temporary suspension is issued, and after an investigation, perpetrators and enablers are permanently removed from the sport system if the evidence demands it.

M-150 — October 9, 2024 — — That, in the opinion of the House, the government should mandate a duty to report abuse, and the duty to report should be immediate, direct, and ongoing, with sufficient interpretive clarity to ensure its application by sport administrators, medical personnel, officials, coaches, and participants.

M-151 — October 9, 2024 — — That, in the opinion of the House, the government should table a report on progress reducing discrimination, harassment, hazing, racism, sexual assault involving an authority figure, athlete-perpetrated sexual assault, and athlete-perpetrated group sexual assault in Parliament under a fixed schedule.

M-152 — October 9, 2024 — — That, in the opinion of the House, the government should ensure that safe sport is an ongoing item on every federal, provincial, and territorial sport meeting agenda to exchange information and share best practices and ensure that there is a seamless sport system from the playground to elite sports.

M-153 — October 9, 2024 — — That, in the opinion of the House, the government should examine sentencing and aggravating factors for sexual abuse and sexual assault in sport and whether they are a sufficient punishment and deterrent.

M-154 — October 9, 2024 — — That, in the opinion of the House, the government should mandate that each national sport organization make public a registry of those whose sport participation is restricted based on violation of the Universal Code of Conduct to Prevent and Address Maltreatment in Sport, and include the name, the location of infraction, the misconduct, the date of the commencement of the investigation, the decision date, the allegations found, the action taken, and the adjudicating body.

M-155 — October 9, 2024 — — That, in the opinion of the House, the government should put in place a registry of convicted offenders in sport, and work with the international sport community so that those who have committed crimes cannot work with athletes and young people in other countries and jurisdictions.

M-156 — October 9, 2024 — — That, in the opinion of the House, the government should mandate that each member of a national sport organization sign a yearly pledge committing to:

(a) zero tolerance on any form of athlete abuse, misogyny, discrimination, harassment, hazing, racism, sexual assault involving an authority figure, athlete-perpetrated sexual assault, and athlete-perpetrated group sexual assault;

(b) immediately reporting any child abuse, neglect or sexual misconduct to law enforcement and the safe sport body; and

M-157 — October 9, 2024 — — That, in the opinion of the House, the government should examine the existing screening program for all persons in authority and a position of trust with athletes and mandate changes based on its findings.

M-158 — October 9, 2024 — — That, in the opinion of the House, the government should mandate all persons in authority and a position of trust who work with athletes to sign an annual pledge recognizing their duty of care to athletes, human rights, athlete rights, and the protections to which they are entitled.

M-159 — October 9, 2024 — — That, in the opinion of the House, the government should mandate each carded athlete to sign an annual declaration that they understand their human rights, athlete rights, and the protections to which they are entitled.

M-160 — October 9, 2024 — — That, in the opinion of the House, the government should mandate that all social media and communication contact between an authority figure in a position of trust be copied to the parent or guardian if the athlete is a minor.

M-161 — October 9, 2024 — — That, in the opinion of the House, the government should examine how harassment officers have performed since the creation of the role and what is required to make them more effective going forward.

M-162 — October 9, 2024 — — That, in the opinion of the House, the government should specify the role of team physicians, their mandates, and the duty of care and protections owed to athletes.

M-163 — October 9, 2024 — — That, in the opinion of the House, the government should examine the rules around billets and mandate new rules to better protect underage athletes.

M-164 — October 9, 2024 — — That, in the opinion of the House, the government should recognize that inequality continues to persist in Canadian sport for women, Indigenous peoples, persons with disabilities, and gender diverse and sexually diverse athletes, and prioritize ending these disparities.

M-165 — October 9, 2024 — — That, in the opinion of the House, the government should collect annual gender statistics for athletes, coaches, safeguarding positions, technical positions, and leadership positions to ensure that Canada achieves gender equality in sport by 2035, or earlier.

M-166 — October 9, 2024 — — That, in the opinion of the House, the government should undertake an anonymous investigation into athlete morbidity and mortality for those who were carded athletes and took performance-enhancing drugs in the 1970s and 1980s.

M-167 — October 9, 2024 — — That, in the opinion of the House, the government should undertake an anonymous survey on current and past performance-enhancing drug use among high school, college, and university sport athletes and determine their drugs of choice, dosages, and sources.

M-168 — October 9, 2024 — — That, in the opinion of the House, the government should ensure Sport Canada or the Canadian Centre for Ethics in Sport has sufficient resources to investigate if there is a cluster of doping cases and to be on guard for tainted performance-enhancing drugs.

Private Members' Business

C-380 — April 18, 2024 — Resuming consideration of the motion of , seconded by , — That Bill C-380, An Act to amend the Canadian Environmental Protection Act, 1999 (plastic manufactured items), be now read a second time and referred to the Standing Committee on Environment and Sustainable Development.

Pursuant to Standing Order 86(3), jointly seconded by:

— February 16, 2024

and — March 21, 2024

Debate — one hour remaining, pursuant to Standing Order 93(1).

Voting — at the expiry of the time provided for debate, pursuant to Standing Order 93(1).


² Response requested within 45 days

House Publications

Notice Paper

Introduction of Government Bills

Introduction of Private Members' Bills

Notices of Motions (Routine Proceedings)

Questions

Notices of Motions for the Production of Papers

Business of Supply

Government Business

Private Members' Notices of Motions

Private Members' Business